Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018 | ||
By: Nasdaq / GlobeNewswire - 10 Dec 2018 | Back to overview list |
|
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present in a fireside discussion at the BMO Prescriptions for Success Healthcare Conference, to be held 12 December 2018 in New York. Mereo BioPharma Presentation Details Date: Wednesday, 12 December 2018 Time: 8:20-8:40 AM ET (1:20-1.40 PM BST) Location: Mandarin Oriental, 80 Columbus Circle, New York, NY 10023 Track & Room: South Salon 1 ABOUT MEREO Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo’s strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. In December 2018, Mereo announced the proposed combination of Mereo and OncoMed Pharmaceuticals, with the transaction expected to close in the first half of 2019. Each of Mereo’s four product candidates has previously generated positive clinical data for Mereo’s target indication or in a related indication. Since inception Mereo has commenced large, randomized, placebo-controlled Phase 2 clinical trials for all four of the product candidates:
FOR FURTHER ENQUIRIES: Mereo BioPharma Group plc Nominated Adviser and Joint Broker Joint Broker UK Public Relations Advisor to Mereo BioPharma US Public Relations Advisor to Mereo BioPharma |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |